NPR’s Rob Stein was reporting on what he described as “among the most exciting developments in cancer research in years” — a ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and ...

A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes ...

Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark ...

Indore: MGM Medical College on Saturday announced its successful treatment of a blood cancer patient using CAR T-cell therapy ...

Chimeric Antigen Receptor or CAR T-cell therapy, the groundbreaking method of treatment, has given new hope to cancer ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

Anktiva is designed to address BCG-unresponsive bladder cancer through its mechanism as an interleukin-15 superagonist.

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.